Prof Dominik Modest speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the PANAMA trial.
The PANAMA trial investigated the use of maintenance therapy with 5-Fluorouracil/Leucovorin (5FU/LV) plus panitumumab or 5FU/LV alone in RAS wildtype metastatic colorectal cancer (mCRC).
Prof Modest explains that there has been a lack of evidence concerning maintenance therapy with EGFR antibodies with this trial aiming to analyse the use of maintenance therapy rather than maintenance and induction therapy together.
He reports that the primary endpoint of progression free survival was improved relatively by 28% stating that the message for this endpoint was clear.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.